32 year old Caucasian male
Switched to ALTUVIIIO: April 2023
Peter presented to the clinic after experiencing numerous bleeding episodes and making frequent calls to the HTC.
Patient Information
Presented due to uncontrolled hemophilia A while on standard half-life prophylaxis therapy
- Over the last 3 years, he experienced hematuria, rectal bleeding, and hematoma of left leg muscle
- Target joints include left elbow, left knee, and right ankle
- Supraventricular tachycardia
- Sinus arrhythmia
- Kidney stones
- Hemophilia-related arthropathy
- Grandfather with severe hemophilia A
- 4 cousins with hemophilia A
- All aunts and mother are asymptomatic carriers
- BP: 147/104
- BMI: 31.1
- Left hip, left knee, and left elbow pain with active range of motion
- Modified PK conducted (Factor infusion and 1-hour post-infusion FVIII level)
- No official PK studies conducted due to Peter living 1+ hours away from clinic
- 1-hour FVIII level after SHL therapy was 166 (11/25/20)
- X-rays showed no acute pathology
Peter’s Path to High Sustained Factor Replacement Therapy, ALTUVIIIO
Diagnosis
- Peter was diagnosed with severe hemophilia A at 2 weeks of age due to a hematoma
After diagnosis
- At 7 years old, Peter presented at an HTC after experiencing numerous bleeding episodes
- Peter's bleeds were uncontrolled
- Frequent HTC calls, hospital visits, and bleeds. Reduced quality of life (experienced hematuria, rectal bleeding, and hematoma of left leg muscle over the last 3 years)
- Peter frequently needed analgesics to manage hemophilia-related pain
Before ALTUVIIIO
- Persistent breakthrough bleeding while on SHL, dosed every 3 days
Considering the switch
Provider and Peter discussed:
- History of noncompliance
- Frequent hospitalizations for emergent bleeds
Comprehensive care team and Peter felt that ALTUVIIIO could benefit him through1,2:
- Improved bleed protection
- Reduced treatment burden
- Improved pain and physical health
After ALTUVIIIO
Switched to ALTUVIIIO: April 2023
- Since starting ALTUVIIIO prophylaxis, Peter’s hemophilia remains well controlled. He is compliant, experiencing less hemophilia-related pain, and has not needed to call the HTC for emergent management
Do you have patients like Peter?
If so, it may be worth it to consider the following:
How good is good enough?
Do patients often say they’re doing fine despite experiencing multiple bleeds each year?
Choosing the right treatment
How would you discuss switching to a more appropriate treatment option, like ALTUVIIIO, with patients like Peter?
Unlocking high sustained factor levels
How could high sustained factor levels and once-weekly dosing with ALTUVIIIO help patients like Peter?
BMI=body mass index; BP=blood pressure; FVIII=Factor VIII; HTC=hemophilia treatment center; PK=pharmacokinetics; SHL=standard half-life.
Other ALTUVIIIO patients who made the switch!
Meet Otis
A 43 year old who works loading trucks and previously treated his moderate hemophilia A with an on-demand therapy.
Meet Noah
A 2 year old who was diagnosed with severe hemophilia A at birth due to a de novo mutation and was treating with prophylaxis therapy.
Indication
References: 1. ALTUVIIIO Prescribing Information. Bioverativ Therapeutics Inc. Waltham, MA. 2. von Drygalski A, et al. N Engl J Med. 2023;388(4):310-318.
